Boehringer, Combotope partner for cancer antibodies

Boehringer Ingelheim has collaborated with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer. Combotope will deploy its platform to discover antibodies, accompanied by a specific antibody characterisation data package. The agreement initially covers multiple oncology targets named by Boehringer Ingelheim. Credit: Tada Images / Shutterstock.com. Boehringer Ingelheim has signed a research collaboration agreement with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer. The partnership will combine Combotope’s SMART-Phage discovery platform with Boehringer Ingelheim’s research and development capabilities, focusing on multiple identified oncology targets. LOA and PTSR Model Bexmarilimab in Acute Myelocytic Leukemia (AML... Reports LOA and PTSR…

Source: Pharmaceutical Technology